SOX新辅助化疗在进展期胃癌的治疗体会

doi:10.3969/j.issn.1009-976X.2021.06.008

摘要/Abstract

摘要： 目的观察奥沙利铂联合替吉奥（SOX方案）新辅助化疗对进展期胃癌手术切除率及临床疗效的影响。方法选取青海省人民医院和南方医科大学附属花都医院2016年5月~2019年7月收治的40例无远处转移的进展期胃癌患者,根据治疗方法的不同分为化疗组（n=20）与非化疗组（n=20）,两组都给予常规手术治疗,化疗组在此基础上给予SOX方案化疗。观察如下指标：化疗组比较化疗前后胃壁、局部淋巴结、门静脉癌栓影像学表现;术中比较两组之间幽门不全梗阻、胃壁组织水肿情况及肿瘤与周围组织的粘连情况;术后比较两组手术切除率、术中出血量、淋巴结转移、平均住院日、R0切除情况及术后肿瘤TNM分期情况。结果化疗组化疗后胃壁变薄,肿瘤缩小,周围肿大淋巴结减少缩小,门静脉癌栓明显好转;与对照组相比,化疗组术中的幽门不全梗阻、胃壁组织水肿情况、肿瘤与周围组织的粘连情况较非化疗组获得了明显的改善（P<0.05）;化疗组的术后切除率高、淋巴结转移少、手术平均住院日短,且提高了R0切除率并降低了术后TNM分期,两组之间差别均具有统计学意义（P<0.05）。结论对于术前评估分期在ⅢA~Ⅵ期无远处转移的进展期胃癌患者,SOX新辅助化疗方案可显著提高根治性手术切除率,且患者耐受性良好。

关键词: SOX方案, 新辅助化疗, 进展期胃癌, 手术

Abstract: Objective To observe the effect of neoadjuvant chemotherapy regimen of oxaliplatin combined with S-1 （SOX regimen） on resection rate and clinical efficacy in patients with advanced gastric cancer. Methods Fourty cases of advanced gastric cancer cases in the Qinghai Provincial People's Hospital and Huadu District People's Hospital of Guangzhou from May 2016 to July 2019 were included. All the cases were divided into chemotherapy group （n=20） and non-chemotherapy group （n=20） accorded to the different treatment methods. Both groups were given conventional surgery, and the chemotherapy group were given SOX chemotherapy on this basis. Observed the following indicators： The patients in the chemotherapy group were compared the imaging findings of the gastric wall, local lymph node, portal vein tumor thrombus before and after the chemotherapy. the pyloric obstruction, the edema of the gastric wall, adhesion of tumor and surrounding tissue were compared intraoperative and surgical resection rate, intraoperative blood loss, lymph node metastasis, average hospital stay were compared postoperative. Moerover, R0 resection and postoperative TNM staging were compared between the two groups. Results Compared with the non-chemotherapy group group, in the chemotherapy group, the gastric wall thin, the tumor shrinkaged, the enlargement of the lymph nodes reduced and disappeared and the portal vein tumor thrombus significantly improved after chemotherapy. The pyloric obstruction and gastric wall edema significantly improved in chemotherapy group （P<0.05）. There were no significant difference in the age, gender and intraoperative blood loss between the two groups （P>0.05）. Surgical resection rate, lymph node metastasis and average hospital stay have difference between the two groups （P<0.05）. The neoadjuvant chemotherapy with SOX also significantly improved the R0 resection and reduced the postoperative TNM staging （P<0.05）. Conclusion Neoadjuvant chemotherapy with SOX can significantly improve the radical resection rate in advanced gastric cancer patients with stage T3 and above, and is well tolerated in patients with advanced gastric cancer, which is worthy of promotion in clinical practice.

Key words: SOX regimen, neoadjuvant chemotherapy, advanced gastric, surgery

中图分类号:

R735.2

曹洪涛, 王晓龙, 陈亮, 林波, 汤婷婷, 马克强, 嵇腾飞, 曹天生, 王健, 张文伟, 杨建荣, 卢卓才, 由田, 何青青, 黄敬敏, 周堤侠. SOX新辅助化疗在进展期胃癌的治疗体会[J]. 岭南现代临床外科, 2021, 21(06): 631-635.

CAO Hong-tao, WANG Xiao-long, CHEN Liang, LIN Bo, TANG Ting-ting, MA Ke-qiang, JI Teng-fei, CAO Tian-sheng, WANG Jian, ZHANG Wen-wei, YANG Jian-rong, LU Zhuo-cai, YOU Tian, HE Qing-qing, HUANG Jin-min, ZHOU Ti-xia. Experience in the treatment of SOX neoadjuvant chemotherapy in advanced gastric cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 631-635.

参考文献

[1] Baba H, Mori M, Shimizu M, et al.A case of a solitary splenic metastasis from gastric cancer[J]. Cancer Chemother Pharmacol, 2019, 116(4): 336-343.
[2] Boku N, Ryu MH, Kato K, et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4)[J]. Ann Oncol, 2019, 30(2): 250-258.
[3] Chin K, Ishizuka N, Takashima A, et al.Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT[J]. Gastric Cancer, 2019, 19(1): 606.
[4] Fukuda K, Arigami T, Yanagita S, et al.A Case of Advanced Gastric Cancer Showing Pathological Complete Response after Neoadjuvant Chemotherapy with S-1 and Oxaliplatin[J]. Gan To Kagaku Ryoho, 2019, 46(3): 471-473.
[5] Han G, Shi J, Mi L, et al.Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer[J]. Future Oncol, 2019, 15(14): 1617-1627.
[6] Hu SB, Liu CH, Wang X, et al.Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer[J], 2019, 17(1): 3.
[7] Kataoka N, Hiramatsu S, Yasuda K, et al.A Case of Advanced Gastric Cancer with Liver Metastases Treated with Curative Conversion Therapy after S-1 plus Oxaliplatin[J]. Gan To Kagaku Ryoho, 2019, 46(13): 1925-1927.
[8] Matsui H, Shimizu Y, Tachikawa H, et al.Locally Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Ramucirumab plus Paclitaxel-Case Report[J]. Gan To Kagaku Ryoho, 2019, 46(10): 1565-1567.
[9] Miyamoto H, Hirakawa T, Morimoto J, et al.A Case in Which pCR Was Obtained by S-1 plus Oxaliplatin Therapy Administered as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2030-2032.
[10] Nishina T, Azuma M, Nishikawa K, et al.Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase Ⅲ study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin[J]. Gastric Cancer, 2019, 22(1): 138-146.
[11] Takahari D.Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer[J]. World J Surg Oncol, 2019, 22(6): 1238-1246.
[12] Tang W, Pan X, Han D, et al.Clinical significance of CD8 (+) T cell immunoreceptor with Ig and ITIM domains(+) in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy[J]. Oncoimmunology, 2019, 8(6): e1593807.
[13] Wu K, Zhu Z, He Y, et al.Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis[J]. Evid Based Complement Alternat Med, 2019, 2019: 3821053.
[14] Xiao C, Qian J, Zheng Y, et al.A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China[J]. BMC Cancer, 2019, 98(20): e15696.
[15] Xu R.Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer[J]. Evid Based Complement Alternat Med, 2019, 19(4): 408-416.
[16] Yamamoto A, Akaike H, Kawaguchi Y, et al.Pathologic Complete Response of Advanced Gastric Cancer after Chemotherapy with S-1 and Oxaliplatin and Conversion Surgery-A Case Report[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2536-2538.
[17] Chen GD, Cao BX, Shi Y, et al.Comparisons of effects of SOX and mFOLFOX6 chemotherapy regimens on patients with locally advanced gastric cancer[J]. J Chemother, 2021:1-6.
[18] Yu S, Cai L, Lin F, et al.Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report[J]. Onco Targets Ther, 2019, 12: 7691-7698.
[19] 李涛,陈凛. SOX方案新辅助化疗应用于进展期胃癌的有效性和安全性研究[J].中华胃肠外科杂志,2011,14(2):104-106.
[20] Zheng S.A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study[J]. J Gastric Cancer, 2019, 84(4): 819-827.